Arca
Skip to content
Tools
Tools

PDGFRA: Platelet-derived growth factor receptor alpha

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis.

  • Drugs that act on it: 6
  • Approved: 4
  • In phases 1 to 3: 2
  • Sponsors: 6
  • Type: Protein

Who Is On It, and How Far Along

Every drug ChEMBL records acting on PDGFRA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule
  • Antibody

Approved4

  • Sunitinib
  • Avapritinib
  • Ripretinib
  • Olaratumab

Phase 30

    Phase 22

    • Amuvatinib
    • Tovetumab

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • Astex Pharmaceuticals, Inc.117%
      • MedImmune LLC117%

      Modalities

      Drugs on this target by ChEMBL molecule type.

      • Small molecule467%
      • Antibody233%

      The Landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 5 of 6 act as: Platelet-derived growth factor receptor alpha inhibitor; the rest name their own mechanism.
      SunitinibApprovedCPPI CVSmall moleculeInhibitor—54Boxed warning
      AvapritinibApprovedSanofiSmall moleculeInhibitor—15—
      RipretinibApprovedOno PharmaceuticalSmall moleculeInhibitor—6—
      OlaratumabApprovedEli LillyAntibodyAntagonistPlatelet-derived growth factor receptor alpha antagonist1—
      AmuvatinibPhase 2Astex Pharmaceuticals, Inc.Small moleculeInhibitor—0—
      TovetumabPhase 2MedImmune LLCAntibodyInhibitor—0—

      Open Trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 23 in all, from ClinicalTrials.gov.
      Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver MetastasesSunitinib—Enrolling by invitationChiyi Chen2026-11-03
      Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell CarcinomaSunitinibPhase 3Active, not recruitingSun Yat-sen University2026-10-20
      First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in SpainSunitinib—Active, not recruitingBristol-Myers Squibb2026-10-01
      A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and PimitespibSunitinibPhase 2RecruitingGlaxoSmithKline2026-07-08
      An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian CancerSunitinibPhase 2RecruitingBai-Rong Xia2026-06-25
      A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaSunitinibPhase 2RecruitingMemorial Sloan Kettering Cancer Center2026-03-17
      An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)Avapritinib—RecruitingBlueprint Medicines Corporation2025-12-04
      A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in GermanyAvapritinib—RecruitingBlueprint Medicines Corporation2025-12-01
      A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapySunitinibPhase 3RecruitingGlaxoSmithKline2025-10-21
      A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKISunitinibPhase 3Not yet recruitingPeking University Cancer Hospital & Institute2025-09-10
      MRD-positive AML Clinical StudyAvapritinibNot applicableRecruitingInstitute of Hematology & Blood Diseases Hospital, China2025-08-20
      Resistance Profiling Using Functional Imaging and Next Generation Sequencing in Refractory Gastrointestinal Stomal Tumors (GIST)Ripretinib—Not yet recruitingUniversität Duisburg-Essen2025-08-07
      A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid LeukemiaAvapritinibPhase 1 / Phase 2RecruitingThe First Affiliated Hospital of Soochow University2025-06-19
      Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCTAvapritinibPhase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China2025-01-20
      Avapritinib Maintenance for AML With KIT MutationsAvapritinibPhase 2Not yet recruitingRuijin Hospital2025-01-09
      Avapritinib Rollover StudyAvapritinibPhase 4RecruitingBlueprint Medicines Corporation2024-12-24
      89Zr-olaratumab Dosimetry in Participants With PDGFR Alpha Positive Solid Tumours and Soft Tissue SarcomaOlaratumabPhase 1RecruitingTelix Pharmaceuticals (Innovations) Pty Ltd2024-08-05
      Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GISTRipretinibNot applicableRecruitingFirst Affiliated Hospital of Chongqing Medical University2024-07-18
      Avapritinib With Decitabine in Patients With SM-AHNAvapritinibPhase 1RecruitingH. Lee Moffitt Cancer Center and Research Institute2024-03-25
      A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced MalignanciesRipretinibPhase 1 / Phase 2Active, not recruitingDeciphera Pharmaceuticals, LLC2023-07-24
      A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With ImatinibRipretinibPhase 3Active, not recruitingDeciphera Pharmaceuticals, LLC2023-02-17
      First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorsRipretinibPhase 1Active, not recruitingIDRX, Inc., a wholly owned subsidiary of GSK, LLC2022-08-05
      A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With ImatinibRipretinibPhase 3Active, not recruitingDeciphera Pharmaceuticals, LLC2018-09-17

      Diseases Most Associated With It

      Open Targets association score, 0 to 1; all associations
      GIST-plus syndrome
      0.74
      Neoplasm
      0.64
      Cancer
      0.63
      Non-small cell lung carcinoma
      0.60

      Genes and Related Targets

      Complexes and families that share a gene with this target
      Genes
      PDGFRA

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2007, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P16234, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.